Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

With me today are Yvonne Greenstreet, Chief Executive Officer, Bova Tanguilar, Chief Commercial Officer, Krish Pagard, Chief Research and Development Officer, and Jeff Fulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.onilam.com slash events. During today's call, as outlined in slide two, Yvonne will offer introductory remarks and provide some general context. Tova will provide an update on our global commercial progress. Bush will review pipeline updates and clinical progress, and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call to your questions. I'd like to remind you that this call will contain remarks concerning Alnylam's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file of the SEC. In addition, any forward-looking statements represent our views as of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to Yvonne. Yvonne? Thanks, Christine, and thank you, everyone, for joining the call today. As shown in our Q2 results announced today, our 9M is firing on all cylinders. And we're swiftly establishing ourselves as a top-tier biotech company. W...